Hims & Hers’ Next Act: Verticalizing Drug Supply to Fix Margins and Risk
Hims & Hers (HIMS) faces a regulatory and margin squeeze but has clear levers to recapture gross margin and control growth: bring higher-margin production in-house, integrate Eucalyptus, and monetize diagnostics and telehealth scale. This trade lays out an actionable long with entry at $29.00, a stop loss at $24.00 and a target of $40.00 tied to ma…